Citations

Clear

2096 citation(s) found for "Ho, Vincent".

Association of drug industry payments to oncologists and use of guideline-preferred cancer treatments.
Augello, Patrick, Abdelaziz, Abdullah, Guzman, Gabrielle , Galanter, Nina, Chakraborty, Nirjhar , Klimchuk, Maria , Alsamarai, Susan, Rajkumar, S. Vincent, Bach, Peter B. , Gönen, Mithat , Mitchell, Aaron Philip , Winn, Aaron N. , Augello, Patrick , Meza, Akriti Mishra , Abdelaziz, Abdullah , Galanter, Nina , Dusetzina, Stacie B.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 11059-11059

10.1200/jco.2026.44.16_suppl.11059 Get It

11059 Background: Payments from the drug industry to oncologists are common and influence physicians’ prescribing decisions. However, whether payments affect the likelihood that patients receive optimal cancer treatment has not been assessed. Methods: This was a population-based cohort study. We used fee-for-service Medicare claims to identify patients with incident cancer diagnosis (new cancer diagnosis code after >= 1 year with no cancer diagnosis codes) from 2014-2020. We used National Comprehensive Cancer Network (NCCN) Guidelines to identify treatment scenarios (e.g., metastatic melanoma, stage III colon adjuvant therapy) with variation in the clinical benefit among recommended treatment options. The patient cohort corresponding to each scenario was identified using claims. We used NCCN Guidelines to identify the “optimal” treatment for each scenario (defined as the designated “preferred” treatment, with NCCN Evidence Blocks scores used for tiebreaks) at each time point across the study period. The primary outcome was whether a patient received the treatment that was, as of their diagnosis date, the optimal treatment for their cancer (vs. any non-optimal treatment). The primary exposure[s] were whether a patient’s medical oncologist received personal (“general”) payments (source: linked Open Payments data) related to 1) optimal treatment or 2) any non-optimal treatment, during the year prior to the patient’s cancer diagnosis. We fit Poisson-family generalized estimating equations, with physician-level clustering and adjustment for scenario, year, and patient characteristics, to estimate the relative risk (RR) of optimal treatment. Results: There were 14 clinical scenarios comprising 15,835 patients. There were 3,429 (21.7%) patients whose oncologist received payment for the optimal treatment, 4,891 (30.9%) for non-optimal payments, and 1,993 (12.6%) to both payment types. Oncologist receipt of payment for optimal treatment was associated with a greater likelihood (RR=1.07, 95%CI:1.01-1.13), and payment for non-optimal treatment was associated with lower likelihood (RR= 0.94, 95%CI:0.89-0.98) of patients receiving optimal treatment. Associations became stronger as payment dollar value increased; for optimal payments ≥$10,000, RR=1.26 (95%CI:1.02-1.57), and for non-optimal payments ≥$10,000, RR=0.70 (95%CI: 0.49-1.00). An estimated 41.6% of unexposed patients received optimal treatment; versus 52.6%, 29.3%, and 33.8% among patients exposed to ≥$10,000 of payments for optimal treatment only, ≥$10,000 non-optimal payments only, and ≥$10,000 of both payment types, respectively. Conclusions: Industry payments related to the optimal cancer treatment were associated with increased use of the optimal treatment. However, payments related to non-optimal treatments were more common and were associated with decreased use of optimal treatment.
The Prevalence of Fibromyalgia in the General Population and At-Risk Subpopulations: A Systematic Review and Meta-Analysis
D'Souza, R. S., Klasova, Johana, Morsi, Mahmoud, Vincent, Ann, Mohabbat, Arya B. , Whitfield, Savannah, Radlicz, Christopher, Zhitnitsky, Michael, Saini, Camille , Al-Hindawi, Ahmed, Lopez, Kalei, To, Jimmy, Graca, Mateusz, Gill, Benjamin, Her, Yeng F , Hussain, Nasir, D’Souza, Ryan S. , D'Souza, Ryan S , Klasová, Johana , Morsi, Mahmoud , Vincent, Ann , Radlicz, Christopher M. , Sheen, Soun , Wang, Daniel , Zhitnitsky, Michael D., Saini, Chandan, Al‐Hindawi, Ahmed , To, Jimmy, Chitneni, Ahish , Graca, Mateusz, Prokop, Larry J. , Hussain, Nasir

Mayo Clinic

Anesthesia & Analgesia | May 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1213/ane.0000000000008098 | PMID 42201834 Get It

Estimates of fibromyalgia prevalence vary widely worldwide due to differences in diagnostic criteria, study methodology, and population characteristics. Accurate estimates are essential to inform population-level surveillance, guide resource allocation, and highlight disparities in disease recognition and access to care. The objective of this systematic review and meta-analysis was to determine the global prevalence of fibromyalgia in the general population, and secondarily to identify factors moderating prevalence variation and to assess prevalence in defined at-risk subpopulations. Pooled prevalence estimates with 95% confidence intervals (CIs) were calculated using the inverse variance heterogeneity model with Freeman–Tukey transformation. Subgroup analyses were performed by sex, diagnostic criteria, country, and other study characteristics, and meta-regression assessed moderators including publication year and Human Development Index (HDI). Of 21,645 records identified, 1,728 underwent full-text review and 882 studies were included in the final analysis. Across 38 countries and 30,070,032 individuals (188 studies), the pooled fibromyalgia prevalence in the general population was 1.40% (95% CI, 0.49–2.47), with substantial heterogeneity (I 2 = 100%) and very low certainty of evidence. Among at-risk subpopulations (9,771,123 participants; 768 studies), prevalence was markedly higher in autoimmune and inflammatory conditions, such as chronic urticaria (37.1%), interstitial cystitis (30.8%), systemic sclerosis (20.6%), celiac disease (20.5%), and inflammatory bowel disease (19.9%), and elevated in chronic pain, rheumatologic, and post-infection cohorts. Meta-regression identified publication year (β = 0.008, P < .001) and HDI (β = 0.725, P = .002) as significant moderators of prevalence. In conclusion, fibromyalgia affects 1% to 2% of the global population, with substantially higher rates in at-risk subpopulations. Temporal and socioeconomic trends emphasize diagnostic inconsistency and global disparities in care.
Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes (MODIFY-IBD): consensus on obesity and cardiometabolic comorbidities in inflammatory bowel disease using systematic reviews and the RAND/UCLA appropriateness met
Devi, Jalpa , Samaan, Sami , Vincent, Matthew, Coombs, Shannon , Doering, Michelle , Barnes, Edward L, Johnson, A, Yarur, Andres J, Mohamed, Mouhand , Devi, Jalpa , Sehgal, Priya , VINCENT, Matthew, Barnes, Edward L., Yarur, Andrés , Deepak, Parakkal

Mayo Clinic

BMJ Open | May 26, 2026 | Volume: 16 | Issue: 5 | Pages: e115709

10.1136/bmjopen-2025-115709 | PMID 42191195 Get It

Introduction Obesity and related cardiometabolic comorbidities, including hypertension, dyslipidaemia, diabetes, metabolic dysfunction-associated steatotic liver disease and atherosclerotic cardiovascular disease, are increasingly prevalent among individuals with inflammatory bowel disease (IBD). These conditions influence disease activity, therapeutic response, surgical outcomes and overall quality of life, yet evidence remains fragmented. The M odulate O besity and relate D metabolic compl I cations F or Y ielding improvements in IBD outcomes (MODIFY-IBD) initiative aims to synthesise evidence and generate consensus recommendations to guide practice and future research in this area. This study describes a protocol for a structured evidence synthesis and Research ANd Development/University of California, Los Angeles (RAND/UCLA) Appropriateness Method (RUAM) consensus process. Methods and analysis We will conduct three systematic reviews and a structured evidence synthesis organised into three domains: (1) the impact of obesity on IBD outcomes, (2) the burden of cardiometabolic complications in IBD and (3) the management of overweight, obesity and cardiometabolic comorbidities in IBD. A multidisciplinary international panel of gastroenterologists, surgeons, endocrinologists, hepatologists, cardiologists and dietitians will assess each statement using the RAND/UCLA appropriateness method. Panellists will rate the appropriateness of each statement (only those that fall within their area of expertise) on a 1–9 scale (1–3=inappropriate, 4–6=uncertain and 7–9=appropriate), with medians rounded up (eg, 6.5=appropriate). Agreement will be assessed using the RAND Disagreement Index (DI<1.0=agreement). Ethics and dissemination This study will not involve direct patient participation, as it is based on evidence synthesis and expert consensus; therefore, formal research ethics committee approval will not be required. Patient representatives will contribute to the consensus process to provide contextual perspectives but no identifiable data will be collected. Findings will be disseminated through publication in peer-reviewed journals, presentation at major gastroenterology and IBD conferences and communication with professional societies. A lay summary and patient-friendly infographic will also be developed to facilitate translation of recommendations into clinical practice. PROSPERO registration numbers CRD420251178843: a systematic review of the impact of obesity on inflammatory bowel disease outcomes. CRD420251178799: a systematic review of cardiometabolic complications in inflammatory bowel disease. CRD420251174653: management of overweight, obesity and cardiometabolic comorbidities in inflammatory bowel disease: a systematic review.
Temporal relationship between hematoma resolution and functional recovery after middle meningeal artery embolization for chronic subdural hematoma
DeMessie, Bluyé , Essibayi, Muhammed Amir, Karandish, Alireza, Park, Jaewoo , Haranhalli, Neil, Baker, Amanda, Zampolin, R, Brook, A, Lee, S, Adeeb, Nimer, Li, Yan-Lin, Ortega, Diego Alejandro, Cancelliere, N, Diestro, Jose Danilo, Carnevale, Joseph A., Schreiber, Craig , Abecassis, Zachary, Raub, Spencer, Sioutas, Georgios S. , Kvint, Svetlana , Falzon, Andrew, Cantrell, Vance, Holliday, Brian, Maleknia, Pedram D., Cruz-Criollo, Leonardo, Schimmel, Samantha, Musmar, Basel, Alexander, Matthew D. , Zermeno, Jorge Rios, Koul, Prateeka , Aljuboori, Ahmed , Vollherbst, D, Cooper, J , Ogilvy, Christopher S., Al-Mufti, Fawaz, Möhlenbruch, Markus A., Scarcia, Luca, Schirmer, Clemens M., Huynh, Thien, Settecase, Fabio , Tjoumakaris, Stavropoula, Jabbour, Pascal, Vakharia, Kunal, Zanaty, Mario, Ortega-Gutierrez, Santiago, Jones, J, Nasser, Hussein H., Sundararajan, Sri Hari , Mosimann, Pascal J., Nossek, Erez , Raz, Eytan, Kasab, S Al, Spiotta, Alejandro M., Michelozzi, Caterina , Saraceno, Davide , Srinivasan, Visish M., Burkhardt, Jan-Karl, Santini, Pietro Mario, Levitt, Michael R., Lanzino, Giuseppe, Brinjikji, Waleed, Knopman, Jared, Kass-Hout, T, Spears, Julian, Marotta, Thomas, Pereira, Vitor Mendes, Fuschi, Maurizio , Dmytriw, Adam A., Altschul, David J., _, _, Kostynskyy, Alex , Goren, Oded , Oliver, Jeffrey Daniel, Milnerowicz, Małgorzata , Papaxanthos, Jean , Eker, Omer, Barreau, Xavier, Courret, Thomas , Berge, Jerome, Engelhardt, Julien , Diestro, Jose Danilo Bengzon , Li, Yan-Lin , Rios Zermeno, Jorge , Diestro, Jose Danilo B , Li, Yan-Lin , Essibayi, Muhammed Amir , Salim, Hamza , Karandish, Alireza , Khatri, Deepak , Haranhalli, Neil , Zampolin, Richard L. , Adeeb, Nimer , Simonato, Davide , Ortega-Moreno, Diego Alejandro , Cancelliere, Nicole M , Carnevale, Joseph Anthony , Orscelik, Atakan , Abecassis, Zachary A. , Raub, Spencer , Salsano, Giancarlo , Kasem, Rahim Abo , Falzon, Andrew , Abaricia, Jefferson O. , Maleknia, Pedram Daniel , Cruz‐Criollo, Leonardo , Schimmel, Samantha J. , Musmar, Basel , Gajski, Domagoj, Alwakaa, Omar , Ogilvy, Christopher S. , Al‐Mufti, Fawaz , Kalousek, Vladimir , Möhlenbruch, Markus , Scarcia, Luca , Schirmer, Clemens M. , Huynh, Thien , Tawk, Rabih G. , Tjoumakaris, Stavropoula , Jabbour, Pascal , Zanaty, Mario , Ortega-Gutierrez, Santiago , Jones, Jesse , Colasurdo, Marco , Nasser, Hussein, Mosimann, Pascal J , Raz, Eytan , Spiotta, Alejandro M , Castellan, Lucio , Sette, Bruno Del , Panni, Pietro , Srinivasan, Visish M. , Burkhardt, Jan‐Karl , Marnat, Gaultier , Levitt, Michael R. , Lanzino, Giuseppe , Brinjikji, Waleed , Knopman, Jared , Kass‐Hout, Tareq , Spears, Julian , Dmytriw, Adam A. , Altschul, David , Galecio‐Castillo, Milagros , Cespedes, Jorge , Oliver, Jeffrey , Eker, Omer , Barreau, Xavier , Berge, Jérôme , Jecko, Vincent

Mayo Clinic

Journal of Neurosurgery | May 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-12

10.3171/2025.12.jns251884 | PMID 42172679 Get It

OBJECTIVE The objective was to evaluate the trajectories of hematoma resolution and functional improvement after middle meningeal artery embolization (MMAE) for chronic subdural hematoma (cSDH), model the temporal pattern of cSDH resolution, and identify factors associated with favorable outcomes. METHODS This real-world multicenter retrospective study included cSDH patients treated with MMAE at 24 centers between 2019 and 2024. Hematoma thickness was measured at baseline and at follow-up intervals (1–4 weeks, 1–3 months, 3–6 months, 6–12 months, and > 12 months after embolization). Resolution patterns were modeled using exponential decay functions. Modified Rankin Scale (mRS) scores assessed functional outcomes. Good functional outcome was defined as mRS score ≤ 2. Resolution patterns were modeled using exponential decay functions to estimate time to 50% and 80% reduction. Patients were categorized as complete resolution (≥ 99%) or by quartile of the remaining distribution (substantial [73%–98%], moderate [53%–73%], partial [27%–53%], minimal [< 27%]). The primary outcome was good functional status (mRS score ≤ 2). RESULTS The authors analyzed a total of 1781 patients with 2295 cSDHs who underwent MMAE. The mean ± SD age was 72.8 ± 12.4 years and 68.1% of patients were male. The initial mean hematoma thickness was 15.31 ± 6.53 mm, decreasing to 5.24 ± 5.91 mm at final follow-up (mean reduction 64.3% ± 42.1%). Resolution followed an exponential decay pattern, with an estimated time to 50% reduction of 1.8 months and to 80% reduction of 8.9 months. Complete resolution occurred in 1031 of 2224 patients (46.4%) with complete follow-up. The median (IQR) mRS score improved from 1 (0–3) at baseline to 0 (0–2) at > 12 months. Good functional outcomes were more common in patients with complete versus minimal resolution (68.9% vs 35.0%, p < 0.001). Achieving ≥ 73% resolution within 90 days was associated with better outcomes (good outcome in 76.9% of those with ≥ 73% resolution vs 67.3% in those without, p < 0.001). Neurological deterioration was the strongest predictor of lack of good outcome (23.7% in patients with neurological deterioration vs 82.4% without, p < 0.001). CONCLUSIONS After MMAE for cSDH, reduction in hematoma thickness follows a predictable exponential decay pattern. Greater extent (≥ 80%) and faster timing (within 90 days) of resolution are valuable prognostic indicators. Functional outcomes improve progressively through 6–12 months after the procedure. The relationship between resolution extent and functional outcomes provides quantitative benchmarks for evaluating treatment response.
D22-04 Demographics, Disparities, and Donor Dynamics: A Comprehensive Evaluation of US Lung Transplant Trends (1988-2025)
Chinnamuthu, R, Bohra, R, Fernandes, W, Fernandes, B C, Cho, T, Phadke, R, Senthilkumar, V, Geetha, H Shanmugavel, Chinnamuthu, Rajaeaswaran, Bohra, Rhea, Fernandes, Bolivia Crocete Aloysia, Phadke, R, Geetha, Harinivaas Shanmugavel

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.6657 Get It

Abstract Purpose This analysis aims to provide a comprehensive overview of lung transplantation trends in the United States from January 1, 1988, through January 31, 2025. By examining key variables such as recipient ABO blood group, donor type (deceased or living), demographic factors, and geographic distribution, the goal is to highlight the evolution and current state of lung transplantation practices. Methods Data were obtained from the Organ Procurement and Transplantation Network (OPTN), encompassing all reported lung transplants during the specified time period. Relevant metrics included the number of transplants per year, recipient characteristics (blood type, race/ethnicity, gender, and age), donor type (deceased versus living), and state-level transplant volumes. Simple descriptive statistics (e.g., frequencies and percentages) were used to identify trends and capture the distribution of transplants among different demographic groups and geographic regions. Results A total of 55,435 lung transplants were performed in the United States between 1988 and early 2025. The vast majority (over 99%) utilized deceased donors, underscoring the limited role of living-donor lobar transplantation, with only 253 procedures reported nationally. Among recipients, ABO blood group O was the most common (∼45%), followed by group A (∼40%), group B (∼11%), and group AB (∼4%). Male recipients represented approximately 57% of transplants, while females accounted for 43%. Regarding race/ethnicity, White non-Hispanic patients constituted roughly 80% of all recipients, with Black non-Hispanic (8%) and Hispanic/Latino (8%) recipients forming smaller but significant proportions. Age distribution data revealed that individuals aged 50 to 64 years received nearly half of all lung transplants, and those over 65 years composed about a quarter of total recipients, reflecting a gradual shift in acceptance criteria favoring older adults. Geographically, California reported the highest volume of lung transplants, attributable to its large population and multiple high-volume transplant centers, while other states such as Florida, Ohio, North Carolina, and Missouri also demonstrated notable activity. Conclusion Lung transplantation in the United States has witnessed substantial expansion in both volume and scope since 1988, with the majority of procedures involving deceased donor lungs. A small number of living-donor lung transplants, while demonstrating innovative clinical possibilities, remains limited. The demographic profile of recipients continues to shift, evidenced by a growing proportion of older adults and a predominance of ABO type O and White, non-Hispanic recipients. Despite these advancements, persistent gaps in access, particularly among underrepresented racial and ethnic groups, highlight the need for further refinement in organ allocation policies and broader support services. This abstract is funded by: None
C66-19 Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Artery Pressure Ratio in Prognosis of Portopulmonary Hypertension Patients Undergoing Liver Transplant
Ghosh, S, Saunders, H, Assis, M, Corro, R, Frias, J E Sinclair De, Khanijo, A, Milian, R Diaz, Menser, T, Reddy, P, O’Sullivan, S, Patel, P, Torp, K, Burger, C D, Franco, P Moreno, Saunders, Hollie , Corro, Rosa, FRÍAS, JORGE SINCLAIR DE , Milian, Ricardo Diaz , Menser, T, O'Sullivan, S, Torp, Klaus D. , Franco, P. Moreno

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5865 Get It

Abstract Rationale Transthoracic echocardiography (TTE) is a very useful measure of cardiac function in patients with pulmonary hypertension (PH), along with right heart catheterization, which is considered to be the gold standard of measurement. It is non-invasive, quick and a good screening tool to assess the function of a failing right ventricle against elevated pulmonary pressures. Portopulmonary hypertension (POPH) is defined as PH associated with portal hypertension. The Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Artery Pressure (TAPSE/SPAP) ratio has been found to be an effective prognosticator in different subtypes of PH. This study focuses on the role of TAPSE/SPAP ratio in prognosis of patients with POPH undergoing liver transplantation. Methods This was a single-center retrospective study of POPH patients undergoing liver transplantation at Mayo Clinic Florida from June 2003 to December 2023. It included patients with POPH with a mean pulmonary pressure &gt;20 mm Hg undergoing liver transplantation. Patients with incomplete TTE data, coexisting renal failure on dialysis and requiring liver retransplant were excluded. This study included 27 patients. The last TTE report before liver transplantation was used for data analysis. The TAPSE/SPAP ratio was investigated as predictor of all-cause mortality following liver transplant using Cox regression and area under ROC curve. (Brackets contain 95% C.I.) Time to death after liver transplantation was considered. Patients were followed till August 1, 2024. (The correlation of this ratio-TAPSE/SPAP with some catheterization measured pulmonary pressures and indices have been included in Table 1.) Results Among 27 patients, 13 were female, 14 male. The most common causes of liver failure in these patients were non alcoholic fatty liver disease (NASH) and alcoholic liver disease. Rarely, some etiologies like sarcoidosis, autoimmune hepatitis, primary sclerosing cholangitis and hepatitis B/C were present. There were 7 deaths among total of 27 patients. The hazard ratio (HR) of TAPSE/SPAP for overall mortality by Cox regression was 0.01 (0.00-0.58), p = 0.03. The area under ROC curve was 0.76 (0.55-0.96), p = 0.01 [Also for TAPSE alone, the area under ROC curve was 0.74 (0.51-0.97), p = 0.05] Conclusion This study infers that TAPSE/SPAP ratio seems to be a good predictor of survival in POPH patients undergoing liver transplant, with a higher ratio associated with decreased all-cause mortality. It suggests that TAPSE alone might also be a good predictor with higher TAPSE associated with decreased mortality. This abstract is funded by: None
zA58-04 Rising Mortality From Pulmonary Hypertension in the Aging US Population: A CDC Wonder Database Analysis From 1999 to 2020
Singh, A, Singh, A, Shah, S H, Jena, A, Khanal, S, Shah, S H, Jena, A, Khanal, S

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5509 Get It

Abstract Rationale Pulmonary hypertension (PH) is a progressive, heterogeneous group of disorders leading to right heart failure and death. Despite advances in management, population-level mortality trends among older adults remain poorly characterized. Understanding these long-term trends is essential for designing equitable, population based interventions. Methods We analyzed mortality data for adults aged 65 years and above using the CDC WONDER database from 1999 to 2020. PH related deaths were identified using ICD 10 codes (I27.0, I27.2,I27.8,I27.9). Age adjusted mortality rates (AAMR) per 100,000 population were calculated and stratified by sex, race and comorbid conditions including hypertension, type 2 diabetes mellitus and congestive heart failure. Temporal trends were evaluated using joinpoint analysis to estimate average annual percent change (AAPC) with corresponding p-values. Results From 1999 to 2020, a total of 141,243 PH related deaths occurred among US adults aged 65 years and above, corresponding to an overall AAMR of 9.1 per 100,000 (95% CI, 8.9-9.3). Annual mortality increased from 5.2 in 1999 to 13.4 in 2020, a 2.6-fold rise (AAPC +3.8%; p &lt; 0.001). Females accounted for 63.7% of all PH deaths and had higher mortality than males (10.8 vs 7.2 per 100,000). Black individuals experienced the highest mortality (12.5 per 100,000), exceeding rates among White (8.7) and Hispanic (7.9) counterparts. The proportion of PH deaths associated with cardiometabolic comorbidities rose substantially, with the largest annual increase seen in PH with coexisting HTN (+4.9% per year), followed by CHF (+4.6%) and T2DM (+4.1%). Conclusions Despite therapeutic progress, overall PH related mortality among older U.S. adults rose significantly from 1999 to 2020. Persistent sex and race based disparities highlight inequities in disease burden and access to care. The increasing coexistence of cardiometabolic comorbidities suggests evolving pathophysiology and emphasizes the need for prevention focused, multidisciplinary strategies. Future work should explore modifiable risk factors and healthcare system determinants driving these trends to inform targeted public health and policy interventions. This abstract is funded by: None
C23-22 Catheter Directed Thrombolysis Versus Systemic Therapy in Pulmonary Embolism: A Decade of Experience From the National Inpatient Sample (2010-2021)
Singh, A, Singh, A, Shah, S H, Jena, A, Khanal, S, Jena, A

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.3486 Get It

Abstract Rationale High and intermediate risk pulmonary embolism (PE) contributes significantly to in hospital morbidity and 5-10% of in hospital deaths. Thrombolytic therapy either via systemic intravenous tissue plasminogen activator (IV-tPA) or catheter directed thrombolysis (CDT) remains central to management, however, comparative national data on utilization and outcomes of thrombolytic therapy for PE remain limited. Methods Using the National Inpatient Sample data from 2010 to 2021, adult hospitalizations for acute PE were identified using ICD 9 code 415.1 and ICD 10 code I26. Cases receiving IV-tPA or CDT were identified using procedural codes. Temporal trends, in-hospital mortality, length of stay (LOS) and complications were compared between treatment groups using weighted analyses. Results Among 1,940,718 hospitalizations with acute pulmonary embolism, the use of thrombolytic therapy increased from 2010 to 2021 for both systemic intravenous tissue plasminogen activator (IV-tPA) and catheter-directed thrombolysis (CDT). Utilization of IV-tPA rose from 1.8% to 2.%, while CDT increased from 1.4% to 3.9%. Compared to IV-tPA, patients treated with CDT were more likely to be older (42.7% vs 39.3% were aged 65 years or above) and male (50.8% vs 48.7%). CDT was associated with significantly lower in hospital mortality (6.7% versus 11.1%, p &lt; 0.01), shorter median length of stay (5 versus 6 days, p &lt; 0.01) and fewer discharges to facilities (13.7% versus 19.4 %, p &lt; 0.01). Rates of major complications were lower in the CDT group, including intracranial hemorrhage (0.4% versus 1.2%), cardiac arrest (1.7% versus 7.3%), myocardial infarction (4.7% versus 5.1%) and need for mechanical ventilation (6.7% versus 16.1%). However, use of extracorporeal membrane oxygenation (0.7% versus 0.2 %) and surgical embolectomy (1.2% versus 0.7%) was higher among CDT patients. Conclusions From 2010 to 2021, utilization of thrombolytic therapy, particularly catheter-directed techniques increased among PE hospitalizations. CDT was associated with lower in hospital mortality, shorter stays and fewer complications compared to systemic IV-tPA. These findings support the expanding role of catheter based interventions as a preferred therapeutic approach for patients with high and intermediate risk pulmonary embolism. Further prospective studies are warranted to confirm long term outcomes and optimize patient selection for CDT. This abstract is funded by: None
C71-16 Diagnostic Accuracy of Genomic Classifier in Patients With Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Studies Published up to 2025
Singh, A, Singh, A, Jena, A, Phadke, R, Paudel, E O’Shea, PAUDEL, ERIN E O'SHEA

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2784 Get It

Abstract Rationale The diagnosis of interstitial lung disease (ILD) requires a multidisciplinary discussion (MDD), in which high-resolution computed tomography (HRCT) and histopathology play key roles. Genomic classifiers have recently been introduced for clinical use, in which lung tissue obtained via transbronchial forceps biopsy undergoes whole-transcriptome RNA sequencing followed by gene expression analysis. These molecular tools are particularly valuable in establishing a diagnosis of idiopathic pulmonary fibrosis (IPF) in patients without a definite usual interstitial pneumonia (UIP) pattern on imaging. Although genomic classifiers are increasingly utilized in clinical practice, data on their diagnostic performance continue to evolve, warranting an updated analysis of the current evidence. Methods A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. Comprehensive search of PubMed, MEDLINE, Embase, Scopus and the Cochrane Library were performed through October 2025 using predefined terms including “genomic classifier,” “Envisia,” “UIP,” and “interstitial lung disease.” Eligible studies were which enrolled adult patients with ILD of uncertain etiology in whom genomic classifiers were compared with histopathologic or MDD based reference standards. True positive, false positive, false negative, and true negative data were extracted to calculate pooled estimates of sensitivity, specificity and the area under the receiver-operating characteristic curve (AUROC) using a random-effects bivariate model. Results Six studies comprising 347 patients met inclusion criteria, with sample sizes ranging from 24 to 98 participants. Across studies, sensitivity ranged from 59% to 85% and specificity from 75% to 100%. The pooled sensitivity was 68% (95% CI, 60-76%; P &lt; 0.001) and specificity 77% (95% CI, 70-85%; P &lt; 0.001), with an estimated AUROC of 0.73 (95% CI, 0.65-0.81) indicating discriminative performance. In two studies evaluating clinical impact, incorporation of genomic classifier data into MDD increased diagnostic confidence in ILD subtyping by 30-50%. No major adverse events related to transbronchial tissue acquisition were reported. Conclusions Genomic classifiers represent a promising, less invasive adjunct for identifying UIP patterns in ILD, demonstrating good overall diagnostic accuracy. Incorporating classifier results within MDD frameworks enhances diagnostic confidence and may reduce the need for surgical lung biopsy in appropriately selected patients. However, small study sizes, potential funding bias and limited accessibility highlight the need for larger, independently conducted prospective studies to further define their role in future IPF diagnostic algorithms. This abstract is funded by: None
A105-21 Mapping Health Disparities: Pneumonia and Chronic Kidney Disease Mortality Across Demographics
Chinnamuthu, R, Bohra, R, Fernandes, W, Fernandes, B C, Cho, T, Senthilkumar, V, Phadke, R, Lim, A, Geetha, H Shanmugavel, Chinnamuthu, Rajaeaswaran, Bohra, Rhea, Fernandes, Bolivia Crocete Aloysia, Phadke, R, Geetha, Harinivaas Shanmugavel

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.922 Get It

Abstract Purpose This study aimed to analyze mortality trends among patients with pneumonia and chronic kidney disease in the United States from 1999 to 2020. By examining patterns across urbanization levels, racial and ethnic groups, geographic regions, and sex, the study sought to identify significant changes over time and potential disparities in mortality outcomes. Methods Mortality data were extracted from the CDC WONDER database for patients diagnosed with pneumonia (ICD-10: J09-J18) and chronic kidney disease (ICD-10: N18). Trends were analyzed using Annual Percent Change (APC) with 95% confidence intervals (CI). Joinpoint regression was utilized to identify significant shifts in mortality trends over time. The analysis was stratified by urbanization level (Large Central Metro, Large Fringe Metro, Medium Metro, Small Metro, Micropolitan), ethnicity (American Indian or Alaska Native, Asian or Pacific Islander, Black or African American, White), census region (Northeast, Midwest, South, West), Hispanic origin (Hispanic or Latino, Not Hispanic or Latino), and sex (Female, Male). Results From 2018 to 2020, significant increases in mortality were observed across all demographic and geographic categories. Urban areas, particularly Large Central Metro (APC = 39.4026%, p = 0.0008) and Small Metro (APC = 37.0284%, p = 0.0004), experienced the most pronounced rises. Ethnic disparities were evident, with Black or African American (APC = 49.9199%, p &lt; 0.000001) and Hispanic or Latino (APC = 61.5742%, p &lt; 0.000001) populations showing the highest mortality increases. By census region, the Midwest (APC = 35.7843%, p = 0.0004) and South (APC = 34.7972%, p = 0.0016) had the most significant spikes. Both females (APC = 36.0664%, p = 0.0004) and males (APC = 35.1504%, p &lt; 0.000001) experienced substantial mortality increases, with females showing slightly higher rates. Conclusion The findings reveal significant increases in mortality from 2018 to 2020 across all analyzed categories, with notable disparities among racial, ethnic, and geographic groups. These trends highlight the need for further investigation into underlying causes and targeted interventions to address inequities. Clinical implications The results underscore the importance of addressing disparities in healthcare access and outcomes, particularly for Black or African American and Hispanic or Latino populations. Clinicians should focus on early diagnosis, effective management of comorbidities, and equitable resource distribution to mitigate mortality risks in high-risk groups. This abstract is funded by: None